Pamrevlumab

A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN) moving towards the end of the year. The Analyst Mizuho’s Difei Yang upgraded shares of FibroGen from...